John D. Isaacs
YOU?
Author Swipe
View article: Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study
Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study Open
Pfizer, BMA Foundation, JGW Patterson Foundation and Newcastle Hospitals Charity.
View article: Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis
Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis Open
Background Dendritic cells are professional antigen presenting cells with the ability, in their immature state, to induce tolerance in T cells. A protocol to develop phenotypically stable tolerogenic dendritic cells (TolDC) was developed i…
View article: Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis
Comparative Effectiveness of Abatacept Versus Adalimumab in Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis Open
Objective The effect of the shared epitope (SE) and valine at position 11 (Val11) of HLA–DRB1 on the activation of CD4 + T cells is expected to be diminished by abatacept, a costimulation blocker. However, published evidence on the value o…
View article: Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) Study: Protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for Rheumatoid Arthritis
Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) Study: Protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for Rheumatoid Arthritis Open
Background: Dendritic cells are professional antigen presenting cells with the ability, in their immature state, to induce tolerance in T-cells. A protocol to develop phenotypically stable tolerogenic dendritic cells (TolDC) was developed …
View article: POS1371 A UNIQUE CIRCULATING SOLUBLE SERUM MEDIATOR PROFILE, TREG EXPANSION AND IL-6 INDUCED STAT3 PHOSPHORYLATION IN CD4+ T CELLS ARE BIOMARKERS OF DISEASE FLARE IN RHEUMATOID ARTHRITIS
POS1371 A UNIQUE CIRCULATING SOLUBLE SERUM MEDIATOR PROFILE, TREG EXPANSION AND IL-6 INDUCED STAT3 PHOSPHORYLATION IN CD4+ T CELLS ARE BIOMARKERS OF DISEASE FLARE IN RHEUMATOID ARTHRITIS Open
View article: POS0455 Is there a difference in the incidence of major adverse cardiovascular events in rheumatoid arthritis diagnosed since 2000 compared with osteoarthritis
POS0455 Is there a difference in the incidence of major adverse cardiovascular events in rheumatoid arthritis diagnosed since 2000 compared with osteoarthritis Open
View article: POS0670 PATTERNS OF STEROID USE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS DURING THE FIRST 12 MONTHS OF TREATMENT WITH BIOLOGICS
POS0670 PATTERNS OF STEROID USE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS DURING THE FIRST 12 MONTHS OF TREATMENT WITH BIOLOGICS Open
View article: POS0724 NEUTROPHIL DYSFUNCTION IN EARLY RHEUMATOID ARTHRITIS AND ITS IMPACT ON CLINICAL PHENOTYPE AND INTERFERON SIGNALLING PATHWAYS
POS0724 NEUTROPHIL DYSFUNCTION IN EARLY RHEUMATOID ARTHRITIS AND ITS IMPACT ON CLINICAL PHENOTYPE AND INTERFERON SIGNALLING PATHWAYS Open
View article: OP0150 DRUG-FREE REMISSION IS CHARACTERISED BY EXPANSION OF CITRULLINATED VIMENTIN-REACTIVE IMMUNE-REGULATORY CD4+CD39+TIGIThi T CELLS IN ACPA+ RHEUMATOID ARTHRITIS
OP0150 DRUG-FREE REMISSION IS CHARACTERISED BY EXPANSION OF CITRULLINATED VIMENTIN-REACTIVE IMMUNE-REGULATORY CD4+CD39+TIGIThi T CELLS IN ACPA+ RHEUMATOID ARTHRITIS Open
View article: Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data
Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data Open
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi d…
View article: Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritis
Pre-treatment GlycA measurement provides no additional predictive utility beyond routine clinical measures in patients with rheumatoid arthritis Open
View article: Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis
Time-independent disease state identification defines distinct trajectories determined by localised vs systemic inflammation in patients with early rheumatoid arthritis Open
We identified 4 distinct trajectories in early RA, differentiating RA into localised vs systemic inflammation. Our results highlight potential differences in disease pathology and opportunities for further targeted treatment. Inevitably, p…
View article: The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles Open
This work was funded by the UK Medical Research Council and EMIS Health.
View article: OA07 Patient-reported outcomes as early warning signals of flare following drug cessation in rheumatoid arthritis
OA07 Patient-reported outcomes as early warning signals of flare following drug cessation in rheumatoid arthritis Open
Background/Aims Withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) in remission offers an opportunity to reduce medication burden, but carries a risk of arthritis flare which requires ra…
View article: Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study
Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study Open
Objectives Huge advances in rheumatoid arthritis (RA) treatment mean an increasing number of patients now achieve disease remission. However, long-term treatments can carry side effects and associated financial costs. In addition, some pat…
View article: Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis
Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis Open
Objectives Drug withdrawal in rheumatoid arthritis (RA) in remission can reduce toxicity, but with the risk of flare which requires close monitoring. We explored the potential of patient-reported outcomes (PROs) for flare detection among R…
View article: Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update Open
View article: Bruton's tyrosine kinase – A new target for immune mediated inflammatory diseases?
Bruton's tyrosine kinase – A new target for immune mediated inflammatory diseases? Open
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein that plays a key role in signalling pathways downstream of diverse surface receptors in B-cells and myeloid cells. These include the B-cell receptor itself, Fc receptors including Fcε…
View article: Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT)
Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT) Open
Background Rheumatoid arthritis is a chronic disease of immune dysregulation affecting 1% of United Kingdom adults at an estimated cost to the taxpayer exceeding £5B per annum. Recently, enhanced pathophysiological understanding and a grow…
View article: CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials Open
View article: SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols Open
This work is a further extension of the SPIRIT-DEFINE study, which obtained no external funding. The principal investigator (CY) used internal staff resources, together with additional resources from external partners, to conduct this stud…
View article: Early onset neutropenia in rituximab treated rheumatoid arthritis patients: a case series
Early onset neutropenia in rituximab treated rheumatoid arthritis patients: a case series Open
View article: Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis
Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis Open
Objective Endogenous retroelements (EREs) stimulate type 1 interferon (IFN‐I) production but have not been explored as potential interferonogenic triggers in rheumatoid arthritis (RA). We investigated ERE expression in early RA (eRA), a pe…
View article: Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease
Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease Open
Regulatory T cells (Tregs) are immune regulatory T cells that are vital for controlling inflammation. The role of Tregs in inflammatory diseases namely psoriatic arthritis (PsA) is still poorly understood. The underlying reason being a lac…
View article: Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis
Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis Open
View article: Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study Open
Background Checkpoint inhibitors (CPIs) are widely used in cancer treatment, with transformative impacts on survival. They nonetheless carry a significant risk of toxicity in the form of immune-related adverse events (IrAEs), which may be …
View article: Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis
Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis Open
Efficacy to biologics in rheumatoid arthritis (RA) patients is variable and is likely influenced by each patient’s circulating drug levels. Using modelling and simulation, the aim of this study was to investigate whether adalimumab and eta…
View article: Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions
Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions Open
Objective International trials can be challenging to operationalise due to incompatibilities between country-specific policies and infrastructures. The aim of this systematic review was to identify the operational complexities of conductin…
View article: OA40 Clinical and psychological factors associated with adherence based on a patient self-reported questionnaire: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate (BRAGGS) cohort
OA40 Clinical and psychological factors associated with adherence based on a patient self-reported questionnaire: results from the biologics in rheumatoid arthritis genetics and genomics study syndicate (BRAGGS) cohort Open
Background/Aims To explore the relationship of clinical and psychological factors with adherence based on a patient self-reported questionnaire from a prospective longitudinal study of patients receiving TNFi biologic treatment for rheumat…
View article: Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial Open